photo credit: Cottonbro Studio / Pexels

Key Takeaways

• Dry age-related macular degeneration (AMD) is no longer managed solely through observation, as new therapies now offer opportunities to slow disease progression.
• Geographic atrophy (GA), an advanced form of dry AMD, causes permanent retinal damage, making early detection and treatment planning increasingly important.
• AREDS nutritional supplements remain a valuable management tool for many patients by helping reduce the risk of progression to advanced AMD.
• Recently approved treatments such as SYFOVRE and IZERVAY target the complement system and can slow the growth of geographic atrophy lesions in some patients.
• Emerging gene therapy research may eventually provide longer-lasting, targeted treatments that reduce the need for repeated interventions and further transform AMD care.